Jonathan Havens is co-chair of the Cannabis Law Practice at Saul Ewing Arnstein & Lehr LLP. He also serves as vice chair of the firm’s Food and Beverage Practice and is a member of the firm’s Life Sciences Practice. Jonathan’s unique perspective on cannabis regulation is informed by his congressional, federal agency, and national and international law firm experience.
He counsels state cannabis license applicants and awardees, ancillary service and product providers, investors, management companies, and various other entities that are affected by federal and state marijuana laws, such as long-term care facilities and higher education institutions.
Before entering private practice, Jonathan served as a regulatory counsel with the U.S. Food and Drug Administration (FDA), where he focused on compliance and enforcement related to promotion, advertising, and labeling. Prior to law school, Jonathan held legislative and government affairs positions in which he managed several areas of policy and drafted legislative proposals, and facilitated the development and execution of strategic communications to members of Congress and their staff aides.
This insightful and interactive session will explore what impact the Trump administration has had and will continue to have on the marijuana industry. In addition, Jonathan Havens will offer insights into both the changing federal and state marijuana regulatory landscapes, including offering predictions on what’s to come, and how these changes could affect industry members, consumers, patients, and the research community. Finally, Jonathan will discuss the U.S. Food and Drug Administration’s (FDA) and the U.S. Drug Enforcement Administration’s (DEA) roles in regulating cannabis, and how the FDA’s approval of cannabis-derived products could steer the scheduling debate.